Regulating Academic–Industrial Research Relationships — Solving Problems or Stifling Progress?
- 8 September 2005
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 353 (10), 1060-1065
- https://doi.org/10.1056/nejmsb051758
Abstract
Dr. Thomas Stossel argues for increasing interaction between academic scientists and the companies that manufacture biomedical treatments.Keywords
This publication has 25 references indexed in Scilit:
- Deferiprone therapy for transfusional iron overloadBest Practice & Research Clinical Haematology, 2005
- NIH Rules Make Some Pack, Others PleadScience, 2005
- Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002New England Journal of Medicine, 2005
- Safety and effectiveness of long-term therapy with the oral iron chelator deferiproneBlood, 2003
- American Society of Clinical Oncology: Revised Conflict of Interest PolicyJournal of Clinical Oncology, 2003
- Maintaining the Public Trust in Clinical ResearchNew England Journal of Medicine, 2002
- Conflict of Interest in the Debate over Calcium-Channel AntagonistsNew England Journal of Medicine, 1998
- Thyroid stormPublished by American Medical Association (AMA) ,1997
- The Framing of Decisions and the Psychology of ChoiceScience, 1981
- Priorities in Scientific Discovery: A Chapter in the Sociology of ScienceAmerican Sociological Review, 1957